Please ensure Javascript is enabled for purposes of website accessibility

GE and Danaher Get FTC Clearance for BioPharma Deal

By Howard Smith - Updated Mar 20, 2020 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This $20 billion transaction is expected to close on March 31.

The U.S. Federal Trade Commission (FTC) has cleared the path for the sale of General Electric Co.'s (GE -4.42%) BioPharma unit to Danaher Corp. (DHR -2.88%). The deal was announced in February, 2019. Danaher is a medical company that operates in three segments: life sciences, diagnostics, and environmental & applied solutions.

In a joint statement, the companies announced that signing the consent decree with the FTC has satisfied all needed antitrust requirements, and the deal is expected to close at the end of the month. In addition to the FTC, the statement said the deal has been cleared by the European Commission as well as antitrust authorities from six other countries, including China, Brazil and Israel.

Two people shake hands. Other people stand together.

Image source: Getty Images.

Transforming the company

Current GE CEO Larry Culp took over that role in September 2018, and previously worked at Danaher. Culp looked to turn around the troubled company by shoring up the balance sheet and strengthening its business segments. The deal for the BioPharma unit is expected to bring in net proceeds of approximately $20 billion for GE. 

Culp was quoted as saying: "Today's update represents a critical milestone on our journey to transform GE. The value from this transaction will fortify our considerable sources to de-risk our balance sheet and continue to solidify our financial position."

According to Danaher, GE BioPharma is "a leading provider of instruments, consumables, and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

General Electric Company Stock Quote
General Electric Company
GE
$60.73 (-4.42%) $-2.81
Danaher Corporation Stock Quote
Danaher Corporation
DHR
$250.63 (-2.88%) $-7.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.